Biotech startups struggle with GMP compliance more than established companies because they typically lack the internal infrastructure, experienced personnel, and financial resources needed to build robust quality systems from the ground up. Early-stage companies are simultaneously developing their science, securing funding, and trying to meet regulatory expectations that were designed with mature organizations in mind. The sections below unpack the most common compliance challenges and what you can do about each one.
Why do biotech startups struggle with GMP compliance more than established companies?
Biotech startups face steeper GMP compliance challenges because they are building quality systems, processes, and expertise at the same time as developing their product. Established companies have decades of institutional knowledge, trained personnel, validated processes, and documented systems already in place. Startups must create all of this from scratch, often with limited budgets and small teams wearing multiple hats.
The core difficulty is that GMP compliance is not a one-time project but an ongoing operational commitment. Regulators expect a functioning quality management system, qualified personnel, controlled documentation, and validated processes before a single batch is released. For a startup that may only have a handful of scientists focused on product development, dedicating the time and resources to meet these expectations can feel overwhelming.
There is also a knowledge gap. Founders with strong scientific backgrounds may not have direct experience navigating GMP requirements, interpreting EU or FDA guidance documents, or preparing for regulatory inspections. Without that expertise internally, gaps can accumulate quietly until they surface at a critical moment, such as during a partnership due diligence review or a pre-approval inspection. This is where working with an experienced regulatory and quality services partner can make a meaningful difference in how quickly those gaps are identified and resolved.
What are the most common GMP documentation failures in early-stage biotech?
The most common GMP documentation failures in early-stage biotech include missing or incomplete standard operating procedures, inadequate batch records, poor change control documentation, and a lack of formal deviation and CAPA processes. These failures often stem from teams prioritizing speed over structure in the early stages of development.
Specific documentation pitfalls that frequently appear include:
- Undocumented procedures: Critical processes are performed based on informal knowledge rather than written SOPs, making them unrepeatable and unverifiable.
- Retrospective record-keeping: Batch records or lab notebooks are completed after the fact rather than in real time, which undermines data integrity.
- Uncontrolled document versions: Teams work from different versions of the same document without a formal version control system in place.
- Missing traceability: Raw materials, reagents, or equipment are used in manufacturing without full traceability back to approved suppliers and certificates of analysis.
- Incomplete CAPA records: Deviations are noted but not formally investigated, with no documented root cause analysis or preventive actions.
Good documentation is not bureaucracy for its own sake. It is the evidence that your process is in control and that your product is consistently manufactured to its specification. Regulators rely on documentation to assess whether a company can be trusted to operate independently.
How does scaling up manufacturing create GMP compliance risks?
Scaling up manufacturing creates GMP compliance risks because processes that work at lab or pilot scale do not automatically translate to larger volumes without revalidation, updated documentation, and reassessment of equipment and facilities. Each scale change is a potential source of new variability that must be controlled and documented.
When a biotech startup moves from research-grade production to GMP-compliant manufacturing at commercial or clinical scale, several risk areas emerge simultaneously:
- Process validation gaps: A process validated at one scale may not perform identically at a larger scale. Critical quality attributes and process parameters need to be re-evaluated.
- Equipment qualification: New or larger equipment must be qualified (IQ, OQ, PQ) before use in GMP production. This is often underestimated in terms of time and cost.
- Cleaning validation: Larger vessels and more complex equipment configurations require updated cleaning validation studies to demonstrate no cross-contamination risk.
- Personnel capacity: A team that managed small-scale production may not have the headcount or training to manage GMP operations at a larger scale without additional hires or external support.
Planning for scale-up with GMP compliance in mind from the beginning, rather than retrofitting compliance after the fact, significantly reduces the risk of costly delays or batch failures.
What GMP requirements apply to biotech startups working with CDMOs?
Biotech startups working with contract development and manufacturing organizations (CDMOs) remain responsible for GMP compliance even though manufacturing is outsourced. EU GMP guidelines make clear that the marketing authorization holder or sponsor cannot transfer regulatory responsibility to a CDMO. You must qualify your CDMO, define responsibilities in a written technical agreement, and maintain oversight of their activities.
Key GMP requirements when working with a CDMO include:
- Supplier qualification: Auditing the CDMO before engagement and at regular intervals to confirm their GMP status and capabilities.
- Technical agreements: A written contract that clearly defines which GMP activities each party is responsible for, including batch release, change control, and deviation management.
- Batch record review: The sponsor retains the right and responsibility to review batch documentation and approve or reject batches.
- Change control oversight: Any changes the CDMO makes to processes, equipment, or materials that could affect your product must go through a formal change control process that you approve.
- Quality oversight meetings: Regular communication with the CDMO to review quality metrics, deviations, and upcoming changes.
Outsourcing manufacturing does not mean outsourcing accountability. Regulators will hold the sponsor responsible if a CDMO fails to meet GMP standards on a product bearing the sponsor’s name.
When should a biotech startup build an in-house QMS versus outsourcing it?
A biotech startup should consider building an in-house quality management system when it has sufficient personnel to maintain it, a pipeline that justifies the ongoing investment, and a long-term plan to hold a marketing authorization. Outsourcing QMS support makes more sense for early-stage companies that need GMP-compliant systems quickly without the overhead of a full internal quality team.
The decision comes down to a few practical factors:
- Stage of development: Pre-clinical and early clinical stage companies often benefit from outsourced QMS support, which gives them a functional system without hiring a full quality team before it is truly needed.
- Pipeline size: A company with one product in Phase I has different needs than one managing multiple assets across different regulatory jurisdictions.
- Regulatory pathway: If you are heading toward a Biological License Application or Marketing Authorization Application, you will need an internalized QMS well before submission. Building that capability takes time, so planning ahead matters.
- Budget and headcount: A QMS is only as good as the people maintaining it. If you cannot dedicate qualified personnel to managing it, a hybrid model where an external quality partner provides QMS infrastructure and oversight while you build internal capability can bridge the gap effectively.
How can biotech startups prepare for their first GMP inspection?
Biotech startups can prepare for their first GMP inspection by conducting a thorough internal audit against the applicable GMP guidelines, closing identified gaps before the inspection date, training all staff on inspection readiness, and ensuring that documentation is complete, accessible, and current. Preparation should begin months in advance, not weeks.
A structured approach to inspection readiness includes:
- Gap assessment: Map your current quality systems against EU GMP Annex requirements or FDA 21 CFR Part 211 (or Part 600 for biologics) to identify areas that need remediation.
- Mock inspection: Run a simulated inspection with an experienced quality professional acting as the inspector. This surfaces procedural gaps and prepares staff for how to respond to questions.
- Document readiness: Ensure all SOPs, batch records, validation reports, and quality agreements are finalized, approved, and version-controlled. Inspectors will request documentation quickly, and disorganized records create a poor impression.
- Staff training: Every person who may interact with an inspector needs to understand their role, know where to find documents, and be able to speak clearly about their responsibilities without overstepping.
- Facility and equipment review: Walk through your facility with GMP eyes. Inspectors notice labeling, cleanliness, segregation of materials, and the calibration status of equipment.
The most common mistake startups make is underestimating how much time remediation takes once gaps are identified. Starting preparation early gives you the runway to fix problems properly rather than rushing through cosmetic fixes that an experienced inspector will see through.
How Starodub supports biotech startups with GMP compliance
We work with biotech startups at every stage of development to help them build and maintain GMP-compliant systems that are practical, scalable, and inspection-ready. Our team brings hands-on regulatory and quality experience across small molecules, biologics, and advanced therapies, so we understand the specific pressures early-stage companies face when trying to meet GMP expectations with lean resources.
Here is how we help:
- GMP gap assessments: We review your current quality systems against applicable EU GMP guidelines and identify the most critical gaps to address first.
- QMS setup and outsourcing: We can build and maintain a GMP-compliant quality management system on your behalf, giving you a functional QMS without the overhead of a full internal quality team.
- CDMO qualification and oversight: We support supplier qualification, technical agreement drafting, and ongoing CDMO oversight so your outsourced manufacturing stays within GMP expectations.
- Inspection readiness support: We conduct mock inspections, prepare your team, and help close documentation gaps before your first regulatory inspection.
- Scale-up compliance planning: We help you anticipate and address the GMP implications of manufacturing scale-up before they become costly problems.
If your startup is navigating GMP compliance for the first time or preparing for a critical regulatory milestone, get in touch with our team to discuss how we can support you.
Related Articles
- When should a company outsource its regulatory submissions?
- How does digital transformation affect GMP compliance requirements?
- What is GMP compliance and why does it matter?
- What is the difference between HTA and regulatory approval?
- What are EMA requirements?
This content was generated with the help of AI and it may contain mistakes
